ProMetic Life Sciences Inc. ABOUT PROMETIC LIFE SCIENCES INC.
ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparation, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Europe, Russia, Australia and Asia.

Industries:
Medical/Pharmaceuticals | Biotechnology
Contact Information:
Frederic Dumais
Senior Director, Communications and Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
+1.450.781.0115

Latest

Feb 14, 2019, 07:00 ET Prometic retains investment bank for strategic transactions

LAVAL, QC, Feb. 14, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI), (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced that it has engaged Lazard to review and execute key...


Dec 19, 2018, 07:30 ET Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences

LAVAL, QC, Dec. 19, 2018 /CNW/ - The Board of Directors of Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has named Prof. Simon Best...


Dec 05, 2018, 09:34 ET Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

Clinical-regulatory pathway defined following recent meetings with regulatory authorities Pivotal Phase 3 clinical trial design finalized to support regulatory submissions in the U.S. and Europe...


Nov 28, 2018, 07:00 ET Prometic Provides Corporate Update

LAVAL, QC, Nov 28, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") has previously announced a series of initiatives to lengthen its cash...


Nov 14, 2018, 20:39 ET Prometic Reports Third Quarter 2018 Financial Results and Highlights

Extension of maturity dates of Line of Credit and OID Loans to September 2024 Implementation of cost control measures to significantly reduce operational burn and extend cash runway Substantial...


Nov 14, 2018, 12:51 ET Prometic Closes its Extension of Debt Maturities to 2024

Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 One of a number of measures underway to extend cash runway Significant reduction in R&D costs of up to $30...


Nov 12, 2018, 17:34 ET Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast

LAVAL, QC, Nov. 12, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the third quarter ended...


Oct 29, 2018, 07:00 ET Prometic Announces Extension of Debt Maturities to 2024

Maturity Date of Line of Credit to be Extended from November 2019 to September 2024 Maturity Date of Long-Term (OID) Loans to be Extended from July 2022 to September 2024 LAVAL, QC, Oct. 29, 2018...


Oct 16, 2018, 06:30 ET Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA

Implementation plan for additional analytical assays and in-process controls confirmed Company finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing...


Sep 05, 2018, 12:23 ET Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic

LAVAL, QC, Sept. 5, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported today that it will host a Key Opinion Leader meeting on PBI-4050, a novel treatment ...


Aug 14, 2018, 18:07 ET Prometic Reports Second Quarter 2018 Financial Results and Highlights

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen) Submitted plan to FDA regarding filing of...


Aug 10, 2018, 07:15 ET Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics

PBI-4050 reduces the activation of hepatic stellate cells, the major cells involved in liver fibrosis PBI-4050 decreases liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway AMPK acts as...


Aug 07, 2018, 14:21 ET Prometic to report its second quarter 2018 financial results and hold conference call / webcast

LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the second quarter ended June...


Aug 07, 2018, 07:00 ET Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050

Rare Pediatric Disease Designation granted for the treatment of patients with Alström syndrome Third Rare Pediatric Disease Designation obtained by Prometic LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ -...


Jun 22, 2018, 12:38 ET Prometic conference call to present progress report on AGM corporate action plan

LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on...


Jun 22, 2018, 07:00 ET Prometic Presents New Data on NASH Drug Candidate PBI-4547

New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity New data to be...


May 22, 2018, 13:31 ET Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis

Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity New clinical data presented at the American Thoracic Society 2018 International Conference...


May 15, 2018, 17:44 ET Prometic reports its 2018 first quarter highlights and financial results

Q1 results support expected 2018 full year spending decrease of approximately $15M Sale of excess plasma inventory completed in April contributing $14M to proforma cash runway of $91M Clinical...


May 10, 2018, 17:13 ET Prometic reports on its 2018 annual and special meeting of shareholders highlights

LAVAL, QC, May 10, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today reported the highlights from its 2018 annual and special meeting...


Apr 30, 2018, 06:30 ET Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial

Clinical data presented at the Clinical Immunology Society Annual Meeting in Toronto, Canada on April 27-28, 2018 Pivotal clinical trial meets primary and secondary endpoints Clinical data...


Apr 12, 2018, 06:30 ET Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial

New clinical data presented at the International Liver CongressTM 2018 PBI-4050 decreased insulin resistance in the liver Fat biopsies further demonstrate PBI-4050 clinical activity Clinical activity ...


Apr 03, 2018, 07:00 ET Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer

Bruce Wendel is an accomplished, senior pharma executive with 37 years of industry experience LAVAL, QC, April 3, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)...


Mar 28, 2018, 21:25 ET Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients

Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment Cardiac MRI indicates PBI-4050 reversed trend of fibrosis progression...


Mar 28, 2018, 20:59 ET Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities

Lead drug candidates (PBI-4050 and RYPLAZIM™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data 52week average PBI-4050 treatment in Alström Syndrome...


Mar 26, 2018, 07:00 ET Prometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / Webcast

LAVAL, QC, March 26, 2018 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the fourth quarter and financial...